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Background: This pilot open noncontrolled study was designed to assess the efficacy of intra-articular injections of
a solution combining hyaluronic acid (HA) and chondroitin sulphate (CS) in the treatment of outpatients affected
by knee osteoarthrosis.
Findings: Thirty patients with knee OA have been included. The primary objective was to assess clinical efficacy as
measured by pain and Lequesne’s index. Secondary objectives were to assess potential effect of the treatment on
ultrasound parameters, safety and biomarkers of cartilage metabolism and joint inflammation. After a selection visit
(V1), the study treatment was administered 3 times on a weekly basis (V2, V3, V4). Follow-up was planned 6 (V5)
and 12 weeks (V6) after the first intra-articular injection. Efficacy results showed a reduction in mean pain at V3 and
V6 and in functional impairment, the most marked changes being measured at the two follow-up visits (V5 and V6).
Although statistical significance was not achieved due to small sample size, a clear tendency towards improvement
was detectable for ultrasound assessments as well as biomarkers. Except for a mild injection site hematoma for
which the drug causal relationship could not be excluded, no adverse effect of clinical relevance was recorded
during the study.
Conclusion: Although this pilot study was performed according to an open design only, the ultrasound as well as
biomarkers changes strongly suggest a non-placebo effect. These preliminary results call now for a randomized
controlled study to confirm the clinical relevance of the observed results.
Trial registration: #ISRCTN91883031
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Ultrasonography, BiomarkersFindings
In the treatment of osteoarthritis (OA), it is now agreed
that surgical procedures should be at least delayed, and
even avoid inasmuch as possible.
Hyaluronic acid (HA) is a component of the synovial
fluid, the lubricating effect of which is related to its
viscoelastic properties. There is a large agreement that* Correspondence: yhenrotin@ulg.ac.be
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reproduction in any medium, provided the orearly manifestations of OA are related to changes in the
viscoelasticity of the synovial fluid which account for a
decrease in the protective action of the cartilage: such
deterioration appears mainly due to a decrease in the
concentration and molecular weight of synovial HA.
HA injections into the joint may compensate for this
deficit in elasticity, thereby improving articular lubrica-
tion. There is a large body of data regarding HS biocom-
patibility, its toxicology as well as its metabolism [1-4].
Regarding HA clinical efficacy in knee OA, a number
of studies are available, some of them performed accord-
ing a double-blind placebo-controlled design [5-7].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(EULAR) recommendations published in 2003, « there is
evidence to support the efficacy of HA in the manage-
ment of knee OA both for pain reduction and functional
improvement » which may induce pain relief « for sev-
eral months » [8].
Structovial CS (Pierre Fabre Médicament) is a medical
device combining a chondroitin sulphate (CS) (30 mg/mL)
and HA (12 mg/mL) to treat knee OA. The biocompatibil-
ity of both products has been assessed during Structovial
CS development. The role of CS is twofold: i) optimizing
HA’s rheological behaviour, due to specific interactions
[9,10]; ii) regulating cartilage metabolism, as a substrate
for polysulphated glycosaminoglycans synthesis as well as
an inhibitor of catabolic cytokines and metalloproteinases
synthesis (11-13).
The primary objective of this study was to provide
some clinical, sonographic, biologic parameters of 3
weekly intra-articular injections of HA/CS in knees
affected by OA over a period of 12 weeks.
Secondary objectives were to: i) assess the treatment
effect on ultrasound (US) parameters; ii) analyze biomar-
kers known as related to cartilage metabolism and to
joint inflammation; and iii) assess the treatment safety.
Methods
This was a single-centre, open-label, uncontrolled study
(Trial registration #ISRCTN91883031) designed to as-
sess intra-articular injections of HA/CS in knee OA.
Patients
Inclusion criteria were: male or female patients aged
≥ 45 and ≤ 80 years; suffering from internal and/or ex-
ternal femoro-tibial OA: meeting the criteria of the
American College of Rheumatology (ACR) (14) (pain of
the knee and crepitus on active motion or morning stiff-
ness < 30 minutes or age >50 years); lasting for at least
6 months; pain ≥ 40 mm as measured on a visual
analogue scale (VAS); stage II or III within the previous
year according to the radiological classification of
Kellgren and Lawrence [11]); OA deemed to justify a
treatment with intra-articular HA according to the in-
vestigator; patient’s written, informed consent.
Non-inclusion criteria were related to any circumstances
likely to interfere with the study treatment, namely: symp-
tomatic femoro-patellar arthrosis or hip arthrosis on the
same side, concomitant skeletal disease (Paget disease,
rheumatoid arthritis, ankylosing spondylitis. . .); former or
concomitant treatment (intra-articular corticosteroids,
topical or oral NSAIDs, anti-arthritis slow acting treat-
ment, recent surgery. . .); individual characteristics in-
compatible with a drug trial (pregnancy or lack of
contraception, serious concomitant disease, participation
in a clinical trial within the preceding 30 days. . .).Participation in the study could be prematurely withdrawn
at the patient’s or investigator’s initiative, e.g. in case of a
significant adverse event.
Patients were not allowed to take any pain relief medi-
cation (eg, NSAIDs, analgesics) or any OA therapy
(eg, diacerein, glucosamine, CS). In the event of severe
pain, and if necessary, patients were permitted to take 1
gram tablets of acetaminophen, 1 at a time, up to 4
times per day, with a minimum of 4 hours between
tablets. If the recommended dosage of acetaminophen
was insufficient, it was permitted to take a NSAID.
Study schedule
The selection period ran from Day -21 to Day -1 (V1).
The patients participated in the study from Day 0 to Day
84. The investigational drug was a sterile solution of
HA/CS for intra-articular injections: each 2 mL injection
contained 24 mg of HA and 60 mg of CS. It was injected
on a weekly basis, on Days 0 (V2), 7 (V3, one week), and
14 (V4, 2 weeks). Then, Days 42 (V5, 6 weeks) and 84
(V6, 12 weeks) were for follow-up and end-of-study
assessments, which brought to 6 the total of scheduled
visits throughout the study.
Study parameters
Clinical parameters
The main recorded parameters were a Visual Analog
Scale (VAS) to measure spontaneous pain (from 0 = no
pain to 100 = maximum pain), Lequesne’s Algo-
Functional Knee Index [12], concomitant medication as
well as adverse events if any; on V1 (first injection) and
V6 (end-of-study follow-up). Overall assessment of
improvement was assessed by the patient and by the
investigator, using a VAS (from 0 = worsening to 100 =
improvement). The clinical response was assessed at V5
and V6 using the criteria defined by the Osteoarthritis
Research Society International (OARSI) [13]. On V6, the
patients were asked about their satisfaction regarding the
treatment.
Ultrasound parameters
An US examination of the target knee was performed
with a Logic 9 (GE) device using a 10-15 mHz high reso-
lution transducer. Joint fluid was assessed by a longitu-
dinal scan of the suprapatellar recess: grade 0 = no,
grade 1 = fluid only detected when an isometric quadri-
cipital contraction is done by the patient, 2 = fluid even
at rest [14]. Synovial thickness was measured on a longi-
tudinal image of the suprapatellar recess with an
extended knee, with a knee flexed at 545° and on a
transversal scan of the lateral recess. The used value was
the addition of the 3 measurements. A detection (and a
quantification when positive) of any popliteal cyst was
done: 0 = no, 1 = yes (in cc).
Table 1 Demographic and baseline characteristics of
included patients




Age (years) n (%)
mean ± SD 61.5 ± 9.4
<45 years 2 (6.7)
45 to 55 years 7 (23.3)
>55 to 65 years 8 (26.7)
>65 to 80 years 13 (43.3)
Weight (kg)
mean ± SD 79.6 ± 12.9
Height (cm)
mean ± SD 166.4 ± 9.9
Body mass index (kg/m²) n (%)
mean ± SD 28.8 ± 4.0
<25 kg/m² 6 (20.0)
25 to 30 kg/m² 14 (46.7)
>30 kg/m² 10 (33.3)
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Several biomarkers have been directly measured in the
serum using immunoassays and following the manufac-
turer instruction: inflammation markers [IL-6] (Bio-
source, Fleurus, Belgium), degradation [Coll2-1] (Artialis
SA, Liège, Belgium) and synthesis [CPII] (IBEX tech-
nologies, Montreal, QC, Canada) of type II collagen,
degradation of aggrecan [CS846] (IBEX technologies,
Montreal, QC, Canada) and markers of oxidative stress
[Coll2-1NO2] (Artialis SA, Liège, Belgium) were
performed.
Statistical and ethical considerations
As there was no control group, the efficacy analysis was
mainly descriptive and there was no primary efficacy
parameter. All tests performed were exploratory. All
analyses were made using the statistical analysis software
(SASW) Version 9.1.3 on the UNIX operating system
software. AEs were coded using the MedDRA 10.1.
Quantitative parameters were described using the fol-
lowing descriptive statistics: number of patients, arith-
metic mean, standard deviation (SD), minimum, median
and maximum values, and first and third quartile.
Qualitative parameters were described using frequen-
cies and percentages.
Efficacy parameters (absolute change from baseline)
were analyzed by linear regression on baseline values. As
there was only one treatment group, all analyses were
exploratory.
For the statistical analysis, the date of first dose of
study drug was considered relative Day 0 and the day be-
fore the first dose of study drug was considered Day -1.
Relative days for assessments before, on, or after the
first dose of study drug were calculated as follows):
Relative Day = Date of Assessment – Date of First Dose
(Day 0).
A sample size of 30 patients was considered sufficient
as the study is explanatory.
The study protocol was approved on January 18 2008
by the Ethic Committee of Erasme Hospital, University
of Brussels. The study was conducted in compliance
with the Declaration of Helsinki and its amendments,
the Good Clinical Practices (GCP 1996), and the ISO
14155 regulation.
Results
Disposition and description of patients
From March 10, 2008 to October 13, 2008 a total of 31
patients were screened/selected at the Hôpital Erasme in
Brussels, Belgium. Of these, 30 patients were included in
the study and were treated with HA/CS: all of them
were included in the safety and efficacy analysis sets.
One patient, having completed Visit 5 (6 weeks), with-
drew from the study on Day 101 for its personalconvenience. No major protocol violation was reported
within this study. The sex ratio of the included patients
was 8 M/22 F, with a mean age [±SD] of 61.5 ± 9.4 years.
Demographic data and baseline characteristics of
included patients are summarized in Table 1. Regard-
ing the patients joint condition, the median [range]
time they had knee OA was 28 [5 - 195] months;
most patients (20 [66.7%]) were assessed as Kellgren-
Lawrence Grade II on the basis of their most recent
X-ray. Knee OA history is summarized in Table 2. No
other medical history or concomitant disease was iden-
tified as significant enough to interfere with the study
assessments.
Efficacy parameters
Pain intensity decreased during the study: as compared
to baseline, the change (mean ± SD) was -23.3 ± 22.51 at
Visit 3 (one week) and -36.1 ±28.54 at Visit 6 (12 weeks).
Linear regressions of the absolute changes were per-
formed on the baseline values: the most significant
changes from baseline were measured at Visit 5 (6 weeks)
(p = 0.0008) and at Visit 6 (12 weeks) (p = 0.0042). The
evolution of pain throughout the study is summarized in
Table 3.
Likewise, functional impairment as assessed by
Lequesne’s index decreased during the study: as com-
pared to baseline, the change (mean ± SD) was
-1.34 ± 3.472 at Visit 3 and -3.40 ± 4.193 at Visit 6
(12 weeks). Linear regressions of the absolute changes
Table 2 Osteoarthritis history in included patients
Knee OA History Full Analysis Set (n = 30)
Target knee more painful at Visit 1 n (%)
Left 13 (43.3)
Right 17 (56.7)
Duration of knee OA, months
mean ± SD 44.6 ± 48.7
median, range 28.0, 5-195
Family history n (%)
Yes 7 (23.3)
Kellgren-Lawrence Grade in last X-ray n (%)
Grade II 20 (66.7)
Grade III 10 (33.3)
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cant changes from baseline were measured at Visit 5
(6 weeks) (p = 0.0031) and at Visit 6 (12 weeks)
(p = 0.0012). The evolution of Lequesne’s algo-functional
knee index is summarized in Table 4.
The patient and investigator assessment of global im-
provement changed only marginally throughout the
study. The biggest difference in the VAS scores, for both
the patients and investigators, was measured one week
after the first study injection, but these differences were
not significant.
A clinical response, as assessed by the OARSI criteria
[13], was found in 23 patients (79%) at Visit 5 (6 weeks)
and in 22 (73%) at Visit (12 weeks) 6.
On Visit 6 (12 weeks), most patients reported being
“very satisfied” (n = 13 ; 45%) or “satisfied” (n = 7; 24%)
with their treatment; only 4 patients (14%) patients
claimed to be discontent.
The majority of patients exhibited a clinical response
to treatment at Visit 5 (6 weeks) (79.3%) and Visit 6
(12 weeks) (73.3%).
Regarding ultrasound parameters, the results are sum-
marized in Table 5. A reduction of the synovial thickness
was found from Visit 2 (baseline) to Visit 6 (12 weeks),
especially in patients displaying articular liquid at base-
line; however, statistical significance was not achieved,
probably because of small sample size. Likewise, fewer
patients showed articular effusion at Visit 6 (12 weeks)
(n = 13) as compared to Visit 2 (baseline) (n = 18), but
the difference was not statistically significant.Table 3 Evolution of pain during the study (100-mm VAS: 0 =
Visit 3 (one week) (n = 30) Visit 4 (2 w
Baseline, mm, mean ± SD 71.3 ± 14.71 71.3 ± 14.71
Post-baseline, mm, mean ± SD 48.0 ± 20.76 37.3 ± 21.87
Change, mm, mean ± SD -23.3 ± 22.51 -34.0 ± 26.98
mm = millimetres; n = number of patients; SD = standard deviation.The results obtained for biomarkers are summarized
in Table 6. Mean values of Coll2-1, Coll2-1NO2 and
CPII decreased between Visit 2 (baseline) and Visit 6
(end of the study, 12 weeks). To measure the linear de-
pendency between biomarkers and pain intensity, correl-
ation coefficients were researched between the absolute
change of each biomarker and the absolute change of
pain from Visit 2 (baseline) and V6 (12 weeks). The
coefficients of correlation were mostly negative indicat-
ing that more the biomarker level change is high, less
the pain change is important. Of note, the results
observed on IL-6, with a dramatic reduction from
5825 ± 21720 pg/mL (baseline) to 162 ± 405 pg/mL.
Safety parameters
No severe adverse event was reported throughout the
study.
Of the 30 patients included in the safety analysis, 4
reported an adverse event: injection site haematoma
(n = 1, 3.3%), wrist fracture (n = 1, 3.3%), arthralgia (n = 1,
3.3%), and venous stasis (n = 1, 3.3%). Of mild intensity,
the haematoma was the only reported adverse event for
which a drug causal relationship was not excluded by
the investigator.
No abnormality of clinical relevance was reported in
vital or physical signs monitored during the study.
Discussion
The purpose of this open study was to assess Structovial
CS (Pierre Fabre Médicament), a solution combining chon-
droitin sulphate (CS) (30 mg/mL) and HA (12 mg/mL)
and administered by intra-articular injections, in 45 to
80-year old patients suffering from femoro-tibial OA.
All enrolled patients received 3 intra-articular injec-
tions of a solution of HA/CS over a 3-week period, and
were assessed in 6 clinic visits, up to 10 weeks after their
last injection. Efficacy was assessed through measure of
pain, functional impairment, clinical response, ultra-
sound and biomarkers.
Both pain intensity and functional impairment decreased
during the study. The most significant changes for both
parameters were observed at 6 and 12 weeks after the first
study injection.
The patient and investigator assessment of global im-
provement changed only marginally throughout the
study. The biggest difference in the VAS scores, for bothno pain, 100=maximum pain)
eeks) (n = 30) Visit 5 (6 weeks) (n = 29) Visit 6 (12 weeks) (n = 30)
70.8 ± 14.73 71.3 ± 14.71
31.3 ± 23.76 35.2 ± 24.59
-39.5 ± 29.23 -36.1 ± 28.54
Table 4 Evolution of Lequesne’s algo-functional knee index during the study
Visit 3 (one week) (n = 29) Visit 4 (2 weeks) (n = 29) Visit 5 (6 weeks) (n = 28) Visit 6 (12 weeks) (n = 29)
Baseline, mm, mean ± SD 11.88 ± 2.966 11.88 ± 2.966 11.70 ± 2.849 11.88 ± 2.966
Post-baseline, mm, mean ± SD 10.53 ± 3.287 8.88 ± 2.770 8.21 ± 3.050 8.48 ± 3.483
Change mm, mean ± SD -1.34 ± 3.472 -3.00 ± 3.036 -3.48 ± 3.420 -3.40 ± 4.193
mm = millimetres; n = number of patients; SD = standard deviation.
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after the first study injection, but statistical significance
was not achieved.
The majority of patients exhibited a clinical response
to treatment at 6 weeks (79.3%) and 12 weeks after the
first study injection (73.3%).
No statistically significant changes in ultrasound para-
meters were seen throughout the study, although an im-
provement was found in term of a reduction in number
of effusion and in term of synovial thickness. With a lar-
ger sample size this probable effect on the synovial in-
flammation could be demonstrated.
The 5 measured biomarkers displayed a high variabil-
ity although they tended to decrease in a consistent way
throughout the study.
No serious adverse events, no adverse event leading to
study discontinuation, and no deaths were reported dur-
ing the study.
A total of 4 (13.3%) adverse events (AEs) were
reported throughout the study: injection site haema-
toma, wrist fracture, arthralgia, and venous stasis. The
injection site haematoma was of mild intensity. For this
AE, the investigator did not exclude a relation to the
study drug.
No other change of clinical relevance was observed in
physical examination or vital signs.
On the basis of these results, the discussion should be
balanced. In this non controlled study, the improvementTable 5 Ultrasound Parameters: Full Analysis Set
Ultrasound Parameter
Articular effusion, n (%)
No liquids
Present only at isometric contraction
Present at rest and at isometric contraction
Height by isometric contraction, mm, mean ± SD 18
Synovial thickness in extension, mm, mean ± SD 30
Synovial thickness in 45° flexion, mm, mean ± SD 30
Synovial thickness in external recess, mm, mean ± SD 30
Synovial thickness total of 3 measurements, mm, mean ± SD 30
Popliteal cyst present, n (%) 29
Popliteal cyst volume, mm3, mean ± SD 4
mm = millimeter; n = number of patients; SD = standard deviation; Note: Percentagin clinical parameters (pain intensity, functional impair-
ment) was not clearly greater than that which could be
induced by a placebo in a controlled study. On the other
hand, the structural as well as biomarkers changes sug-
gest a non-placebo effect, as lack of statistical significant
for both “objective” parameters is most probably a con-
sequence of small sample size. In particular, biomarkers
changes appeared quite consistent although statistically
not significant, with a decrease in Coll2-1 (degradation
marker) and in IL-6 and Coll2-1NO2 (markers of oxida-
tive stress and of inflammation). In a previous study,
Hosigawa et al. already showed that intra-articular injec-
tion of hyaluronan was associated with a reduction in
biomarkers in synovial fluid, suggesting that HA could
help maintain normal cartilage metabolism at least in
patients at an early stage of OA and with limited syno-
vitis [15]. The biomarkers are the reflect of cartilage deg-
radation, then directly correlated with the disease
activity (i.e. inflammation and pain). The change in bio-
marker levels due to the medical device over time can
be linked to the change in disease activity. By the way,
the more important is the change in biomarkers, the
more important is the effect on pain.
Overall, the results of this pilot study are consistent
with a favourable benefit/risk ratio of the medical de-
vice used, but they strongly call for undergoing now a
randomized clinical trial with the required statistical
power.Visit 2 (baseline) Visit 6(12 weeks)
30 30
12 (40.0) 17 (56.7)
14 (46.7) 11 (36.7)
4 (13.3) 2 (6.7)
3.20 ± 1.682 13 3.34 ± 1.251
1.72 ± 1.015 30 1.60 ± 0.972
2.06 ± 1.196 30 1.83 ± 1.086
1.81 ± 0.993 30 1.57 ± 0.665
5.58 ± 2.591 30 5.00 ± 2.139
6 (20.7) 30 7 (23.3)
471.09± 869.230 6 2924.73 ± 3783.539
es are based on available information.
Table 6 Biomarkers: Full Analysis Set
Biomarker Coll 2-1 (nM) n= 21 Coll 2-1 NO2 (nM) n = 21 CS-846 (ng/mL) n = 20 CP II (ng/mL) n = 21 IL-6 (pg/mL) n = 18
mean± SD
V2 (baseline) 127± 62 0.44 ± 0.29 92 ± 24 1040± 518 5825± 21720
V6 (D84) 116± 37 0.38 ± 0.18 93 ± 21 1000± 646 162± 405
Change -11 ± 78 -0.06 ± 0.41 1 ± 17 -41 ± 865 -5663 ± 21769
correlation coefficients (biomarkers change vs pain change)
Pearson -0.395 -0.412 -0.021 -0.469 -0.086
p= 0.0766 p= 0.0637 p = 0.9296 p = 0.0319 p = 0.7354
Spearman -0.274 -0.262 0.026 -0.319 0.151
p= 0.2287 p= 0.2512 p = 0.9122 p = 0.1584 p = 0.5500
mL = milliliter; n = number of patients; ng = nanogram; nM = nanomolar; pg = picogram; SD = standard deviation.
Note: Only patients with both a baseline value and a time point value are summarized at Visit 6; Correlation coefficients between the absolute change of each
biomarker and the absolute change of pain from V2 and V6.
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Intra-articular injections of HA is a well-established
therapy for the treatment of knee OA. The study was
designed to support the clinical efficacy and safety data
on the use of HA when combined with CS for intra-
articular injections.
The injection pattern of 1 injection weekly over
3 weeks is the current treatment pattern of most clinical
studies of HA to date and is the treatment pattern of
HA solutions available on the market. The present study
followed this treatment regimen.
Although limited by a lack of control group as well as
small sample size, the results of this pilot study suggest
that intra-articular treatment with HA/CS (Structovial
CS, Pierre Fabre Médicament) is effective and safe in
patients with knee OA. These results should be con-
firmed now by a randomised clinical trial on a bigger
sample size.
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